All
Novel Drug Granted FDA Fast Track in Rare Prostate Cancer Subset
February 13th 2024The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).
Phase 2 Trial Assessing Novel TKI Begins in ALK-Positive NSCLC, Solid Tumors
February 12th 2024Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.
Opdivo Plus Chemo Did Not Improve Progression in EGFR-Mutated NSCLC
February 8th 2024Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.
Tagrisso After Chemoradiation Reduced Progression Risk in NSCLC
February 7th 2024Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when compared with those treated with Imfinzi or subject to observation.